Trials / Completed
CompletedNCT05424523
Effectiveness and Safety of Omalizumab in Children With Allergic Asthma.
A Retrospective Multicenter Study for Assessment of the Effectiveness and Safety of Omalizumab in Children With Allergic Asthma in a Real-world Setting in China
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 6 Years – 11 Years
- Healthy volunteers
- Not accepted
Summary
The study was the non-interventional, retrospective study aimed to assess the effectiveness and safety of omalizumab in children with allergic asthma in China, and described patient profiles and treatment patterns of omalizumab in real-world practice.
Detailed description
This non-interventional, retrospective study aimed to assess the effectiveness and safety of omalizumab in children with allergic asthma in China, and described patient profiles and treatment patterns of omalizumab in real-world practice. This study was designed to use secondary data from medical charts of 25 hospitals. Medical records were reviewed to collect information such as demographics, clinical characteristics, treatment patterns, effectiveness, and AEs for retrospective analysis. Patients with allergic asthma aged 6 -\<12 years treated with omalizumab from July 6, 2018 to September 30, 2020 were identified for medical chart extraction.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Omalizumab | Patients with confirmed diagnosis of allergic asthma, who were prescribed omalizumab |
Timeline
- Start date
- 2021-02-25
- Primary completion
- 2021-06-28
- Completion
- 2021-06-28
- First posted
- 2022-06-21
- Last updated
- 2022-07-05
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05424523. Inclusion in this directory is not an endorsement.